gefitinib, erlotinib / eff Cancer Research Results

GB, gefitinib, erlotinib: Click to Expand ⟱
Features:
selectively targeting the mutant proteins in malignant cells.
epidermal growth factor receptor (EGFR) inhibitors (lung cancer)
eff, efficacy: Click to Expand ⟱
Source:
Type:
Power to enhance an anti cancer effect
Scientific Papers found: Click to Expand⟱
6684- DAP,  GB,    Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
- vitro+vivo, NSCLC, H1975
PDK1↓, eff↑, EGFR↓, Apoptosis↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

PDK1↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:7  Target#:961  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page